Neumentum, Inc.
  • About
  • Leadership
  • Pain
    • Chronic Pain
    • Acute Pain
  • Pipeline
    • NTM-001
    • NTM-006
    • Early Stage
  • Investors
  • Media
  • Contact Us
Select Page

Neumentum to Participate in the Jefferies Virtual London Healthcare Conference

by admin | Nov 5, 2020 | Press Releases

MORRISTOWN, NJ, November 5, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during...

Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China

by admin | Oct 21, 2020 | Press Releases

Neumentum to receive $3MM upfront payment and is eligible to receive total development, regulatory and sales-based milestones of up to an additional $50MM plus royalties   MORRISTOWN, NJ, October 21, 2020 – Neumentum Inc., a pharmaceutical company dedicated to...

Neumentum to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference

by admin | Sep 10, 2020 | Press Releases

MORRISTOWN, NJ, September 10, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during...

Neumentum Announces Two Poster Presentations for Novel Non-opioid, Non-NSAID Analgesic Drug Candidate at PAINWeek 2020

by admin | Sep 3, 2020 | Blog, Press Releases

MORRISTOWN, NJ, September 3, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present two posters with data on NTM-006, a new chemical entity (NCE) non-opioid, non-NSAID analgesic candidate that...

Neumentum Provides Corporate Update on Company’s Pipeline of Non-opioid Analgesic Programs

by admin | Jul 23, 2020 | Press Releases

Neumentum Provides Corporate Update on Company’s Pipeline of Non-opioid Analgesic Programs October 2020 Type C meeting planned with the FDA for NTM-006, an oral new chemical entity with a novel mechanism of action targeting neuropathic pain  Based on recent FDA...

Neumentum, Inc. Chief Executive Officer Scott Shively to Present at BIO Digital Conference

by admin | Jun 7, 2020 | Press Releases

PALO ALTO, Calif., June 5, 2020 – Neumentum, Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, has posted a presentation for digital viewing for the BIO...
« Older Entries
Next Entries »